Title:
Nanocarrier mediated anti-CD47 siRNA delivery
Agreement Value:
$31,000.00
Agreement Date:
Mar 30, 2020 - Mar 31, 2022
Description:
This project involves the preparation of gene therapy transporters for the enhancement of cancer patient immune response. These delivery systems will be used to specifically target cell models of leukemia. This could help to open the door to treatments that are not as generally debilitating to patients. It is of particular interest to target leukemia which have relapsed or returned after initial treatment.
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators.
Location:
Toronto, Ontario, CA M5S 1S8
Reference Number:
172-2020-2021-Q4-944745
Report Type:
Grants and Contributions
Recipient Business Number:
108162330
Additional Information:
This agreement has been amended 1 time(s). The total amended value is $31000 and the end date of this agreements has been modified by 365 days)
Amendment Date
Jan 28, 2021
Recipient's Legal Name:
The Governing Council of the University of Toronto
Federal Riding Name:
University–Rosedale
Federal Riding Number:
35110
Program:
Collaborative Science, Technology and Innovation Program – Ideation Fund
Program Purpose:
The Ideation Fund is intended to encourage, test and validate transformative research ideas generated by teams of NRC scientific personnel and external collaborators with complementary capabilities, acting as a demonstration phase for a continually-evolving suite of research and development (R&D) deliverables at the NRC. The fund supports exploratory research through two mechanisms: the New Beginnings Initiative and the Small Teams Initiative.
NAICS Code:
541710 - R&D in the physical, engineering and life sciences